Hormonal
Roux-en-Y gastric bypass (RYGB) surgery restores gut hormone balance by elevating postprandial GLP-1 and PYY levels, which contributes to sustained weight loss and improved glucose homeostasis.
For patients who have undergone Roux-en-Y gastric bypass, the surgery works largely by changing how gut hormones signal fullness (GLP-1 and PYY). This hormonal shift helps maintain weight loss and improves blood sugar control long-term. If surgery is not an option, new combination drug therapies aim to replicate this hormonal effect.
Indeed, the reported weight loss with ensuing improvement in glucose homeostasis in patients undergoing RYGB surgery or sleeve gastrectomy is associated with elevated postprandial PYY and GLP-1 levels, even one year after surgery [136,137].
Why this rating
Based on multiple cited studies showing consistent elevation of satiety hormones post-surgery, though ghrelin effects are inconsistent.
Source
The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake
Mona Farhadipour et al. · Nutrients · 2021
DOI 10.3390/nu13061839
More from this paper
- Combination therapy using GLP-1 receptor agonists with other hormones (GIP, GCG, or PYY) mimics the beneficial hormonal effects of gastric bypass surgery in non-surgical patients.Good
- Obesity is associated with altered nutrient sensing mechanisms in the gut, specifically region-dependent changes in the expression of amino acid and bitter taste receptors, which may contribute to inconsistent gut hormone fluctuations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →